

**Amendments to the Claims:**

Please cancel claims 9-20, amend the claims, and add new claims as follows.

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

**Claim 1.** (Currently Amended) A ~~formulation device~~ for transdermal electrotransport delivery, comprising an electrotransport reservoir containing an aqueous solution of a drug and a ~~dipeptide~~peptidic buffer, the ~~dipeptide-peptidic~~ buffer comprising a polypeptide having a chain of 2 to 5 amino acids and having an isoelectric pH at which the ~~dipeptide-polypeptide~~ carries no net charge, the ~~dipeptide-polypeptide~~ having at least 2 pKa's which are separated by no more than about 3.5 pH units, the solution having a pH which is within 1.0 pH units of the isoelectric pH.

**Claim 2.** (Currently Amended) The ~~formulation device~~ of claim 1, wherein the isoelectric pH of the ~~dipeptide-polypeptide~~ is between about 3 and 10.

**Claim 3.** (Currently Amended) The ~~formulation device~~ of claim 1, wherein the ~~dipeptide~~polypeptide is present in the solution at a concentration of at least about 10 mM.

**Claim 4.** (Currently Amended) The ~~formulation device~~ of claim 1, wherein the ~~dipeptide~~polypeptide includes at least one amino acid selected from the group consisting of His, Tyr, Arg, Cys, Lys, Asp and Glu.

**Claim 5.** (Currently Amended) The ~~formulation device~~ of claim 1, wherein the ~~dipeptide~~polypeptide includes His.

**Claim 6.** (Currently Amended) The ~~formulation device~~ of claim 1, wherein the ~~dipeptide~~polypeptide is Gly-His.

**Claim 7.** (Currently Amended) The ~~formulation~~ device of claim 1, wherein ~~dipeptide~~ the polypeptide is selected from the group consisting of Asp-Asp, Gly-Asp, Asp-His, Glu-His, His-Glu, His-Asp, Glu-Arg, Glu-Lys, Arg-Glu,, Lys-Glu, Arg-Asp, Lys-Asp, His-Gly, His-Ala, His-Asn, His-Citruline, His-Gln, His-Hydroxyproline, His-Isoleucine, His-Leu, His-Met, His-Phe, His-Pro, His-Ser, His-Thr, His-Trp, His-Tyr, His-Val, Asn-His, Thr-His, Try-His, Gin-His, Phe-His, Ser-His, Citruline-His, Trp-His, Met-His, Val-His, His-His, Isoleucine-His, Hydroxyproline-His, Leu-His, Ala-His, Gly-His, Beta-Alanylhistidine, Pro-His, Carnosine, Anserine, Tyr-Arg, Hydroxylysine-His, His-Hydroxytlysine, Ornithine-His, His-Lys, His-Ornithine and Lys-His.

**Claim 8.** (Currently Amended) The ~~formulation~~ device of claim 1, wherein the drug comprises a polypeptide or a protein.

**Claim 9. - 20.** (Canceled)

**Claim 21.** (New) The device of claim 1, wherein the peptidic buffer is at a pH one of being slightly higher than the polypeptide's pI in a cathodic reservoir from which a drug therein is to be delivered and being slightly lower than the polypeptide's pI in an anodic reservoir from which a drug therein is to be delivered.

**Claim 22.** (New) The device of claim 1, wherein the peptidic buffer is at a pH one of being 0.5 to 1 unit higher than the polypeptide's pI in a cathodic reservoir from which a drug therein is to be delivered and being 0.5 to 1 unit lower than the polypeptide's pI in an anodic reservoir from which a drug therein is to be delivered.

**Claim 23.** (New) The device of claim 1, wherein the device is iontophoretic and comprising a donor electrode contacting the reservoir containing the drug.

**Claim 24.** (New) The device of claim 1, wherein the device is iontophoretic and further comprising a second reservoir counter to the reservoir containing the drug, the second reservoir containing electrolyte and a peptidic buffer, the peptidic buffer comprising a polypeptide having a chain of 2 to 5 amino acids and having an isoelectric pH at which the polypeptide carries no net charge, the polypeptide having at least 2 pKa's which are separated by no more than about 3.5 pH units, the solution having a pH which is within 1.0 pH units of the isoelectric pH.

**Claim 25.** (New) A method of making a device for transdermal electrotransport delivery, comprising including in the device an electrotransport reservoir containing an aqueous solution of a drug and a peptidic buffer, the peptidic buffer comprising a polypeptide having a chain of 2 to 5 amino acids and having an isoelectric pH at which the polypeptide carries no net charge, the polypeptide having at least 2 pKa's which are separated by no more than about 3.5 pH units, the solution having a pH which is within 1.0 pH units of the isoelectric pH.

**Claim 26.** (New) The method of claim 25, comprising including a polypeptide with an isoelectric pH of between about 3 and 10.

**Claim 27.** (New) The method of claim 25, comprising including the polypeptide in the solution at a concentration of at least about 10 mM.

**Claim 28.** (New) The method of claim 25, wherein the polypeptide includes at least one amino acid selected from the group consisting of His, Tyr, Arg, Cys, Lys, Asp and Glu.

**Claim 29.** (New) The method of claim 25, wherein the polypeptide includes His.

**Claim 30.** (New) The method of claim 25, wherein the polypeptide is Gly-His.

**Claim 31.** (New) The method of claim 25, wherein the polypeptide is selected from the group consisting of Asp-Asp, Gly-Asp, Asp-His, Glu-His, His-Glu, His-Asp, Glu-Arg, Glu-Lys, Arg-Glu, Lys-Glu, Arg-Asp, Lys-Asp, His-Gly, His-Ala, His-Asn, His-Citruline, His-Gln, His-Hydroxyproline, His-Isoleucine, His-Leu, His-Met, His-Phe, His-Pro, His-Ser, His-Thr, His-Trp,

His-Tyr, His-Val, Asn-His, Thr-His, Try-His, Gin-His, Phe-His, Ser-His, Citruline-His, Trp-His, Met-His, Val-His, His-His, Isoleucine-His, Hydroxyproline-His, Leu-His, Ala-His, Gly-His, Beta-Alanylhistidine, Pro-His, Carnosine, Anserine, Tyr-Arg, Hydroxylysine-His, His-Hydroxytlysine, Ornithine-His, His-Lys, His-Ornithine and Lys-His.

**Claim 32.** (New) The method of claim 25, comprising including a polypeptide or a protein as the drug.

**Claim 33.** (New) The method of claim 25, comprising including the peptidic buffer at a pH one of being slightly higher than the polypeptide's pI in a cathodic reservoir from which a drug therein is to be delivered and being slightly lower than the polypeptide's pI in an anodic reservoir from which a drug therein is to be delivered.

**Claim 34.** (New) The method of claim 25, comprising including the peptidic buffer at a pH one of being 0.5 to 1 unit higher than the polypeptide's pI in a cathodic reservoir from which a drug therein is to be delivered and being 0.5 to 1 unit lower than the polypeptide's pI in an anodic reservoir from which a drug therein is to be delivered.